Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men.
Subramanian K, Martinez J, Huicochea Castellanos S, Ivanidze J, Nagar H, Nicholson S, Youn T, Nauseef JT, Tagawa S, Osborne JR. Subramanian K, et al. Among authors: osborne jr. Sci Rep. 2023 May 23;13(1):8321. doi: 10.1038/s41598-023-35567-w. Sci Rep. 2023. PMID: 37221397 Free PMC article.
Prostate-specific membrane antigen-based imaging.
Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Osborne JR, et al. Urol Oncol. 2013 Feb;31(2):144-54. doi: 10.1016/j.urolonc.2012.04.016. Epub 2012 May 31. Urol Oncol. 2013. PMID: 22658884 Free PMC article. Review.
PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
Akhtar NH, Osborne JR, Fareedy SB, Tagawa ST. Akhtar NH, et al. Among authors: osborne jr. Expert Opin Ther Pat. 2013 May;23(5):665-8. doi: 10.1517/13543776.2013.789501. Epub 2013 Apr 13. Expert Opin Ther Pat. 2013. PMID: 23581819
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM. Tagawa ST, et al. Clin Cancer Res. 2013 Sep 15;19(18):5182-91. doi: 10.1158/1078-0432.CCR-13-0231. Epub 2013 May 28. Clin Cancer Res. 2013. PMID: 23714732 Free PMC article. Clinical Trial.
A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.
Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, Larson SM, Bander NH, Scherr DS. Osborne JR, et al. J Urol. 2014 May;191(5):1439-45. doi: 10.1016/j.juro.2013.10.041. Epub 2013 Oct 14. J Urol. 2014. PMID: 24135437 Free PMC article.
Utility of FDG-PET in clinical neuroendocrine prostate cancer.
Spratt DE, Gavane S, Tarlinton L, Fareedy SB, Doran MG, Zelefsky MJ, Osborne JR. Spratt DE, et al. Among authors: osborne jr. Prostate. 2014 Aug;74(11):1153-9. doi: 10.1002/pros.22831. Epub 2014 Jun 9. Prostate. 2014. PMID: 24913988 Free PMC article.
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. Pandit-Taskar N, et al. Among authors: osborne jr. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21. Eur J Nucl Med Mol Imaging. 2014. PMID: 25143071 Free PMC article. Clinical Trial.
215 results